EPISODE · Aug 26, 2024 · 11 MIN
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM
from JACC This Week
In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.
NOW PLAYING
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m